Skip to content

Role of Ayurveda-Virechana Karma and Basti Karma in the management of Obesity with High Lipid Levels

Effect Of Virechana Karma Followed By Triphaladi Yoga Basti On APOLIPOPROTEIN B100 Levels In The Management Of Sthaulya W.S.R. To Obesity Linked Hyperlipidemia: An Open Labelled Single Arm Clinical Study - NIL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/05/111265
Enrollment
30
Registered
2026-05-27
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E669- Obesity, unspecified

Interventions

None listed

Sponsors

Institue Of Teaching and Research in Ayurveda Jamnagar Gujarat India
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients presenting with at least 5 classical signs and symptoms of Sthaulya. Serum LDL level between 100 to 190 mg/dl and/or Serum triglyceride level between 160 to 499 mg/dl and/or Serum cholesterol level more than 240 mg/dl and/or Serum VLDL level more than 30 mg/dl and/or Serum HDL level less than 35 mg/dl. Patients indicated for Virechana Karma and Basti Karma. Patients having BMI between 25 and 35. Waist hip ratio more than 0.95 in men and more than 0.85 in women. Willing and able to participate in the study.

Exclusion criteria

Exclusion criteria: Age below 18 years and above 60 years. Patients having serum LDL level more than 190 mg/dl and/or serum triglyceride level more than 499 mg/dl. Known cases of serious cardiac disorders such as myocardial infarction and angina. Known cases of AIDS and sexually transmitted diseases. Drug induced obesity due to anticonvulsants, antipsychotics, or other medications. Known cases of hypothyroidism. Individuals contraindicated for Virechana Karma and Basti Karma. Patients having uncontrolled hypertension, diabetes mellitus, or any other systemic illness. Pregnant and lactating women.

Design outcomes

Primary

MeasureTime frame
Reduction in Apolipoprotein B100 levels. Reduction in Serum Triglycerides, LDL, VLDL and Total Cholesterol. Reduction in BMI. Increase HDL level.Timepoint: 20-25 Days

Secondary

MeasureTime frame
Improvement in signs and symptoms of Sthaulya. (Scoring Assessment)Timepoint: Once after 4 weeks

Countries

India

Contacts

Public ContactProf Dr Anup Thakar

Institute Of Teaching and Research in Ayurveda

anup_thakar@yahoo.com9427776660

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026